Mental health economic studies from developing countries reviewed in the context of those from developed countries

Acta Psychiatrica Scandinavica

Volumn 101, Issue 2, 2000, Pages 87-103

  Shah, A ^a,c   Jenkins, R ^b  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c CENTRAL AND NORTH WEST LONDON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Economics; Mental disorders; Mental health services

Indexed keywords

COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; COST UTILITY ANALYSIS; DATA BASE; DEVELOPED COUNTRY; DEVELOPING COUNTRY; ECONOMICS; MEDICAL INFORMATION; MENTAL DISEASE; MENTAL HEALTH; MENTAL HEALTH SERVICE; PRIORITY JOURNAL; REVIEW; WORLD HEALTH ORGANIZATION;

CLINICAL TRIALS; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DEVELOPED COUNTRIES; DEVELOPING COUNTRIES; HUMANS; MENTAL DISORDERS; MENTAL HEALTH SERVICES;

EID: 0033983222     PISSN: 0001690X     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0447.2000.9r004.x     Document Type: Review

References (207)

1. 1. Smith K, Shah A, Wright K, Lewis G. The prevalence and costs of psychiatric disorders and learning disabilities. Br J Psychiatry 1995;166:9-18.
2. 2. Maynard A. Cost management: the economist's viewpoint. Br J Psychiatry 1993;163(Suppl. 20):7-13.
3. 3. Andrews G, Hall W, Goldstein G, Lapsley H, Bartels R, Silove D. The economic costs of schizophrenia. Arch Gen Psychiatry 1985;42:537-543.
4. 4. Craig N, Stark C. Health economics in mental health. 2. Economic evaluation. Psychiatr Bull 1997;21:687-691.
5. 5. Donaldson C, Atkinson K, Bond J et al. Should QALYs be programme specific? J Health Econ 1988;7:239-257.
6. 6. Wilkinson G, Williams B, Krekoriaan H et al. QALYS in mental health: a case study. Psychol Med 1992;22:725-731.
7. 7. World Bank. World Development Report 1993. Investing in health. Washington, DC: Oxford University Press, 1993.
8. 8. Murphy JG, Datel WE. A cost-benefit analysis of community versus institutional living. Hosp Commun Psychiatry 1976;27:165-170.
9. 9. Lyade PM, Von Alleman SD, Oakley GP. Congenital hypothyroidism control programs. A cost-benefit analysis. J Am Med Assoc 1979;241:2290-2292.
10. 10. Wiesbrod BA, Test MA, Stien LI. Alternative to mental hospital treatment. II. Economic benefit-cost analysis. Arch Gen Psychiartry 1980;37:400-405.
11. 11. Wiesbrod BA. A guide to benefit-cost analysis, as seen through a controlled experiment in treating the mentally ill. J Health Polit Policy Law 1983;7:808-845.
12. 12. Wiesbrod BA. Benefit-cost analysis of a controlled experiment: treating the mentally ill. J Hum Resources 1981;16:523-548.
13. 13. Frank PJ, Klein S, Jacobs J. Cost-benefit analysis of a behavioural program for geriatric inpatients. Hosp Commun Psychiatry 1982;33:374-377.
14. 14. Bond GR. An economic analysis of psychosocial rehabilitation. Hosp Commun Psychiatry 1984;35:356-362.
15. 15. Ginsberg G, Marks I, Waters H. Cost-benefit analysis of a controlled trial of nurse therapy for neurosis in primary care. Psychol Med 1984;14:683-690.
16. 16. Ten Horn GHMM, Giel R. The feasibility of cost-benefit studies of mental health care. An attempt with a Dutch case register. Acta Psychiatr Scand 1984;69:80-87.
17. 17. Cardin VA, McGill CW, Fallon IRH. An economic analysis: cost benefits and effectiveness. In: Falloon I, ed. Family management of schizophrenia. A study of clinical, social, family and economic benefits. Baltimore, MD: Johns Hopkins University, 1985;115-123.
18. 18. Simmons SA, Perry PJ, Rickert ED, Brown, JL. Cost-benefit analysis of prospective pharmacokinetic dosing of nortryptiline in depressed patients. J Affect Disord 1985;8:47-53.
19. 19. King M. Case finding for at-risk drinking in general practice: cost-benefit analysis. Psychol Med 1986;16: 359-363.
20. 20. Retchin SM, Hillner BE. The cost and benefit of a screening program to detect dementia in old drivers. Med Decision Making 1994;14:315-324.
21. 21. Rupp A. The economic consequences of not treating depression. Br J Psychiatry 1995;166(Suppl. 27):29-33.
22. 22. Shah AK. The measurement of economic burden of psychiatric illness in old age. Aust J Ageing 1995;14:3-5.
23. 23. Shah AK. Economic burden of illness forum. Reply to Shiell. Aust J Ageing 1995;14:7.
24. 24. Beherens C, Henke KD. Cost of illness studies: no aid to decision making? Reply to Shiell et al. (Health policy 8 (1987) 317-323). Health Policy 1988;10:57-60.
25. 24. Beherens C, Henke KD. Cost of illness studies: no aid to decision making? Reply to Shiell et al. (Health policy 8 (1987) 317-323). Health Policy 1988;10:57-60.
26. 25. Shah AK. Dementia and dementia care. Int J Geriatr Psychiatry 1998;13:67.
27. 26. Drummond M. Principles of economic appraisal in health care. Oxford: Oxford University Press, 1989.
28. 27. Knapp M, Beecham J. Costing mental health services. Psychol Med 1990;20:893-908.
29. 28. McCrone P, Weich S. Mental health care costs: paucity of measurement. In: Thornicroft G, Tansella M, ed. Mental health outcomes. Spinger: London, 1996;131-142.
30. 29. Leon AC, Portera L, Wiessman MN. The social costs of anxiety disorders. Br J Psychiatry 1995;166(Suppl. 27): 19-22.
31. 30. Revicici DA, Luce BR, Weschler JM, Brown RE, Adler MA. Cost-effectiveness of clozapine for treatment-resistant schizophrenia patients. Hosp Commun Psychiatry 1990;41:850-854.
32. 31. Davies LM, Drummond MF. Assessing of costs and benefits of drug therapy for treatment-resistant schizophrenia in the United Kingdom. Br J Psychiatry 1993; 162:38-42.
33. 32. Matheson LA, Cook HM, McKenna P, Bosanquet N. Value for money for patients with schizophrenia. Br J Med Econ 1994;7:25-34.
34. 33. Jonnson B, Bebbington P. What price depression? The cost of depression and the cost-effectiveness of pharmacological treatment. Br J Psychiatry 1994;164:665-673.
35. 34. Montgomery SA, Brown RE, Clark M. Economic analysis of treating depression with nefazadone vs. imipramine. Br J Psychiatry 1996;168:768-771.
36. 35. Woods SW, Rizzo JA. Cost-effectiveness of antidepressant treatment reassessed. Br J Psychiatry 1997;170:257-243.
37. 36. Lubeck DP, Mazonson PD, Bowie P. The potential impact of tacrine on expenditure in Alzheimer's disease. Med Interface 1994;7:130-138.
38. 37. Stewart A, Phillips R, Dempsey G. Pharmacotherapy for people with Alzheimer's disease: a Markov-cycle evaluation of five years therapy using donepezil. Int J Geriatr Psychiatry 1998;13:445-453.
39. 38. Stewart A. Economic effects of hepatitis B vaccination in drug misusers in England and Wales. Ment Health Res Rev 1997;4:20-21.
40. 39. Cowley P, Wyatt JR. Schizophrenia and manic-depressive illness. In: Jamison DT et al., ed. Disease control priorities in developing countries. Oxford: Oxford University Press, 1993;661-670.
41. 40. Sen B, Wilkinson G, Mari JJ. Psychiatric morbidity in primary health care. A two-stage screening procedure in developing countries: choice of instruments and cost-effectiveness. Br J Psychiatry 1987;151:33-38.
42. 41. Mezzich JE. Architecture of clinical information and prediction of service utilisation and cost. Schizophr Bull 1991;17:469-473.
43. 42. Hafner H, An Der Heiden W. Effectiveness and cost of community care for schizophrenia patients. Hosp Commun Psychiatry 1989;40:59-63.
44. 43. Salize JH, Rossler W. The cost of comprehensive care of people with schizophrenia living in the community. A cost evaluation for a German catchment area. Br J Psychiatry 1996;169:42-46.
45. 44. Healey A, Knapp M, Astin J et al. Economic burden of drug dependency. Social costs incurred by drug users at intake to the National Treatment Outcome Study. Br J Psychiatry 1998;173:160-165.
46. 45. Healey A, Knapp M, Astin J, Kemp R, Kirov G, David A. Cost-effectiveness evaluation of compliance therapy for people with psychosis. Br J Psychiatry 1998;172:420-424.
47. 46. McCrone P, Thornicroft G, Phelan M, Holloway F, Wykes T, Johnson S. Utilisation and costs of community mental health services. Br J Psychiatry 1998;173:391-398.
48. 47. Schultz RI, Greeney JR, Peterson RW. Management, cost and quality of acute inpatient psychiatric services. Med Care 1983;21:911-928.
49. 48. Beecham J, Knapp M, Fenyo A. Costs, needs and outcomes. Schizophr Bull 1991;17:427-439.
50. 49. Moscarelli M, Capri S, Neri L. Cost evaluation of chronic schizophrenic patients during the first 3 years after first contact. Schizophr Bull 1991;17:421-426.
51. 50. Knapp M, Beecham J, Fenyo A, Hallam A. Community mental health care for former hospital inpatients: predicting costs from needs and diagnosis. Br J Psychiatry 1995;166(Suppl. 27):10-18.
52. 51. Chisholm D, Knapp MRJ, Astin J, Lelliott P, Audini B. The mental health residential care study: predicting costs from resident characterisitics. Br J Psychiatry 1997;170: 37-42.
53. 52. Livingston G, Manela M, Katona C. Cost of community care for older people. Br J Psychiatry 1997;171:56-69.
54. 53. Knapp M, Beecham J. Mental health service costs. Curr Opin Psychiatry 1991;4:275-282.
55. 54. Beecham J, McCrone P. Cost information for commissioners. In: Thornicroft G, Strathdee G, eds. Commissioning mental health services. London: HMSO, 1996; 239-246.
56. 55. Hall W, Goldstien G, Andrews G, Lapsley H, Bartels R, Silove D. Estimating the economic costs of schizophrenia. Schizophr Bull 1985;11:598-610.
57. 56. Croft-Jefreys C, Wilkinson G. Estimated costs of neurotic disorders in UK general practice 1985. Psychol Med 1989;19:549-558.
58. 57. Schneider EL, Guralnik JM. The ageing of America. The impact of health care costs. J Am Med Assoc 1990; 263:2235-2240.
59. 58. Suleiman TG, Ohaeri JU, Lawal RA, Haruna AY, Orija OB. Financial cost of treating out-patients with schizophrenia in Nigeria. Br J Psychiatry 1997;171:364-368.
60. 59. Xiong W, Phillips MR, Wang R, Dai Q, Klienman J, Klienman A. Family-based intervention for schizophrenic patients in China: a randomised controlled trial. Br J Psychiatry 1995;165:239-247.
61. 60. Wang Q, Gong Y, Niu K. The Yantai model of community care for rural psychiatric patients. Br J Psychiatry 1994;165(Suppl. 24):107-113.
62. 61. Isaac MK, Kapur RL. A cost-effective analysis of three different methods of psychiatric case finding in the general population. Br J Psychiatry 1980;137:540-546.
63. 62. Gillis LS, Koch A, Joyi M. The value and cost-effectiveness of a home-visiting programme for psychiatric patients. S Afr Med J 1989;77:309-310.
64. 63. Drummond MF, Mohide EA, Tew M, Streiner DL, Pringle DM, Gilbrert JR. Economic evaluation of a support program for caregivers of demented elderly. Int J Technol Assess Health Care 1991;7:209-219.
65. 64. Wimo A, Mattsson B, Krakau I, Ericksson T, Nelvig A, Karlsson G. Cost-utility analysis of group living in dementia care. Int J Technol Assess Health Care 1995; 11:49-65.
66. 65. De Jonge JVM. A comprehensive public mental health programme in Guinea-Bissau: a useful model for African, Asian and Latin American countries. Psychol Med 1996; 26:97-108.
67. 66. Murray CJL, Lopez AD. The global burden of diseases: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020. Boston, MA: Harvard School of Public Health, WHO and World Bank, 1996.
68. 67. Jenkin R. Reducing the burden of mental illness. Lancet 1997;349:1340.
69. 68. Shah Ak, Ames D. Planning and developing psychogeriatric services. Int Rev Psychiatry 1994;6:15-27.
70. 69. Blue I, Harpam T. The World Bank Development Report 1993; investing in health. Br J Psychiatry 1994;165:9-12.
71. 70. Murthy RS. Economics of mental health care in developing countries. In: Mak FL, Nadelson CC, eds. International review of psychiatry. Washington, DC: American Psychiatric Press, 1996;43-62.
72. 71. Shah AK. The burden of psychiatric disorder in primary care. Int Rev Psychiatry 1992;4:243-250.
73. 72. Hotopf M, Lewis G, Normand C. Are SSRIs a cost-effective alternative to tricyclics? Br J Psychiatry 1996; 168:404-409.
74. 73. Grizenko N, Papineau D. A comparison of the cost-effectiveness of day treatment and residential treatment for children with severe behavioural problems. Can J Psychiatry 1992;37:393-400.
75. 74. Sartorius N. The research component of the WHO mental health programme. Psychol Med 1980;10:175-185.
76. 75. Sartorius N, Jablensky A, Gulbinat W, Ernberg G. WHO collaborative study: assessment of depressive disorders. Psychol Med 1980;10:743-749.
77. 76. Mari JJ, Williams P. Minor psychiatric disorder in primary care in Brazil: a pilot study. Psychol Med 1984; 14:223-227.
78. 77. Anonymous. Diagnosis and classification of mental disorders and alcohol and drug-related problems: a research agenda for the 1980s. Psychol Med 1983;13: 907-921.
79. 78. Cheng TA, Hsu M. A community study of mental disorders among four aboriginal groups in Taiwan. Psychol Med 1992;22:255-263.
80. 79. Abas M, Broadhead JA, Mbape P et al. Defeating depression in the developing world: a Zimbabwean model. Br J Psychiatry 1994;164:293-296.
81. 80. Rumble S, Swartz L, Parry C, Zwarestein S. Prevalence of psychiatric morbidity in the adult population of a rural South African village. Psychol Med 1996;26:997-1007.
82. 81. Hirata ES, Almeida OP, Funari RR, Klien EL. Study on alcoholism: alcoholism in a geriatric outpatient clinic, Sao Paulo, Brazil. Int Psychogeriatrics 1997;9:95-103.
83. 82. Sum T, Gallo JJ. Symptom profiles of depression among general medical service users compared with speciality mental health service users. Psychol Med 1997;27: 1051-1063.
84. 83. Conley RW, Conwell M, Arrill MB. An approach to measuring the cost of mental illness. Am J Psychiatry 1967;124:63-70.
85. 84. Gunderson JG, Mosher LR. The cost of schizophrenia. Am J Psychiatry 1975;132:901-906.
86. 85. Muller CF, Caton CLM. Economic costs of schizophrenia: a post-discharge study. Med Care 1983;21: 92-104.
87. 86. Stoudemire A, Frank R, Hedemark N, Kamlet M, Blazer D. The economic burden of depression. Gen Hosp Psychiatry 1986;8:387-394.
88. 87. Edlund MJ, Swann AC. The economic and social costs of panic disorder. Hosp Commun Psychiatry 1987;38: 1277-1288.
89. 88. Hay JW, Ernst RL. The economic costs of Alzheimer's disease. Am J Pub Health 1987;77:1169-1175.
90. 89. Maynard A, Hardman G, Whelan A. Measuring the social costs of addictive substances. Br J Addiction 1987;82:701-706.
91. 90. Huang LF, Cartwright WS, Hu TW. The economic cost of senile dementia in the United States. Pub Health Rep 103:3-7.
92. 91. Maynard A. Controlled legal addiction. In: Robinson D et al. eds. Proceedings of the 25th Annual Symposium of the Eugenics Society. London: Macmillan, 1988;84-100.
93. 92. Rick DP, Kelman S. Measuring comorbidity and overlap in the hospitalisation cost for alcohol and drug abuse and mental illness. Inquiry 1989;26:249-260.
94. 93. Davies Cm, Drummond MI. The economic burden of schizophrenia 1990;14:522-525.
95. 94. Siegal L, Jones WC, Wilson JO. Economic and life consequences experienced by a group of individuals with panic disorder. J Anxiety Disord 1990;4:201-211.
96. 95. Andrews G. The cost of schizophrenia revisited. Schizophr Bull 1991;17:389-394.
97. 96. Karson CN, McClellan JL, Kasner TM. Assault increases the cost of care among inpatient veterans with schizophrenia. J Nerv Ment Dis 1991;179:702-704.
98. 97. Rice DP, Kelman S, Miller LS. Estimates of economic costs of alcohol and drug abuse and mental illness 1985 and 1988. Pub Health Rep 1991;106:280-292.
99. 98. Kavanagh S, Schneider J, Knapp MRJ, Beecham J, Netten A. Elderly people with cognitive impairment: costing possible changes in the balance of care. Health Soc Care Commun 1993;2:69-80.
100. 99. Kind P, Sorensen J. The costs of depression. Int Clin Psychopharmacology 1993;7:191-195.
101. 100. Rice DP, Miller LS. The economic burden of affective disorders. Adv Health Econ Health Serv Res 1993; 14:37-53.
102. 101. Rice DP, Fox PJ, Max W et al. The economic burden of Alzheimer's care. Health 1993;summer issue:164-176.
103. 102. Schneider J, Kavanagh S, Knapp M, Beecham J, Netten A. Elderly people with advanced cognitive impairment in England: resource use and costs. Ageing Soc 1993; 13:27-50.
104. 103. Ernst RL, Hay JW. The US economic and social costs of Alzheimer's disease revisited. Am J Pub Health 1994; 84:1-4.
105. 104. Gray A, Fenn P. Alzheimer's disease: the burden of disease in England. Health Trends 1993;25:31-37.
106. 105. Ostbye T, Crosse E. Net economic cost of dementia in Canada. Can Med Assoc J 1994;18:1457-1464.
107. 106. Evers SMAA, Ament AJHA. Costs of schizophrenia in The Netherlands. Schizophr Bull 1995;21:141-153.
108. 107. Kavanagh S, Knapp MJR et al. Schizophrenia. Shifting the balance of care. Soc Psychiatry Psychiatr Epidemiol 1995;30:206-212.
109. 108. Cuffel BJ, Jeste DV, Halpain M, Pratt C, Tarke H, Patterson TL. Treatment costs of use of community mental health services for schizophrenia by age cohorts. Am J Psychiatry 1996;153:870-876.
110. 109. Henderson J. The lifetime cost of childhood conduct disorder. Ment Health Res Rev 1997;4:24-25.
111. 110. Lang FH, Forbes JF, Murray GD, Johnstone EC. Service provision for people with schizophrenia. I. Clinical and economic perspective. Br J Psychiatry 1997;171:159-164.
112. 111. Wimo A, Karlsson G, Sandman PO, Corder L, Winblad B. Cost of illness due to dementia in Sweden. Int J Geriatr Psychiatry 1997;12:857-861.
113. 112. Haro JM, Salvador-Curulla J, Cabases VM, Vazquez-Barquero JL and the PSICOST Group. Utilisation of mental health services and costs of patients with schizophrenia in three areas of Spain. Br J Psychiatry 1998; 173:334-340.
114. 113. Yip PSF. Suicides in Hong Kong, Taiwan and Beijing. Br J Psychiatry 1996;169:495-502.
115. 114. Benegal V, Velayudhan A, Kumar CP, Jain S, Janakiramaiah N. The social cost of alcoholism in India. Fourth Workshop on Costs and Assessments in Psychiatry, Venice, 1997.
116. 115. Skavysh VA. How much does suicidology in Russia cost? Fourth Workshop on Costs and Assessments in Psychiatry, Venice, 1997.
117. 116. Solokhina T, Chevtchenko L, Rytik E. The basic trends of economic research in Russian psychiatry. Fourth Workshop on Costs and Assessment in Psychiatry, Venice, 1997.
118. 117. Shapiro S, Sank LI, Shaffer CS, Donovan DC. Cost-effectiveness of individual vs. group cognitive behaviour therapy for problems of depression and anxiety in an HMO population. J Clin Psychol 1982;38:674-677.
119. 118. Hengeveld MW, Ancion FAJM, Rooijmans HGM. Psychiatric consultations with depressed medical inpatients: a randomised controlled cost-effectiveness study. Int J Psychiatry Med 1988;18:33-43.
120. 119. Preskorn SH, Fast GA. Therapeutic drug monitoring for antidepressants: efficacy, safety and cost-effectiveness. J Clin Psychiatry 1991;52(Suppl.):23-33.
121. 120. Scott AIF, Freeman CPL. Edinburgh Primary Care Depression Study: reatment outcome, patient satisfaction, and cost after 6 weeks. Br Med J 192;304:883-887.
122. 121. Forder J, Kavanagh S, Fenyo A. A comparison of the cost-effectiveness of sertraline versus tricyclic antidepressants in primary care. J Affect Disord 1996;38: 97-111.
123. 122. Simon GE, Vonkorff M, Heiligenstein JH et al. Initial antidepressant in primary care: effectiveness and cost of fluoxetine vs. tricyclic antidepressants. J Am Med Assoc 1996;275:1897-1902.
124. 123. Honingfeld G, Patin J. A two-year clinical and economic follow-up of patients on clozapine. Hosp Commun Psychiatry 1990;41:882-885.
125. 124. Meltzer HY, Cola P, Way L et al. Cost-effectiveness of clozapine in neuroleptic-resistant schizophrenia. Am J Psychiatry 1993;150:1630-1638.
126. 125. Jonnson D, Walinder J. Cost-effectiveness of clozapine treatment in therapy-refractory schizophrenia. Acta Psychiatr Scand 1994;92:199-201.
127. 126. Albright PS, Livingston S, Keegan DL, Ingham M, Shrikande S, Lorier JL. Reduction of health-care resource utilisation and costs following the use of risperidone for patients with schizophrenia previously treated with standard antipsychotic therapy. Clin Pharmacoeconomics 1996;11:289-299.
128. 127. Guest JF, Hart WM, Cookson RF, Linstrom E. Pharmacoeconomic evaluation of long-term treatment with risperidone for patients with chronic schizophrenia. Br J Med Econ 1996;10:59-67.
129. 128. Aitchison KJ, Kerwin RW. Cost-effectiveness of clozapine. Br J Psychiatry 1997;171:125-130.
130. 129. May PRA. Cost efficiency of treatments for the schizophrenic patient. Am J Psychiatry 1971;127:118-121.
131. 130. Karon BP, Vandenbos GR. Treatment costs of psychotherapy versus medication for schizophrenics. Prof Psychol 1975;6:293-298.
132. 131. Linn MW, Caffey EM, Klett CJ, Hogarty GE, Lamb R. Day treatment and psychotropic drugs in aftercare of schizophrenic patients. Arch Gen Psychiatry 1979;36: 1055-1066.
133. 132. Tarrier N, Lowson K, Barrowclough C. Some aspects of family intervention in schizophrenia. II: Financial consideration. Br J Psychiatry 1991;159:481-484.
134. 133. Brodaty H, Peters K. Cost-effectiveness of a training program for dementia carers. Int Psychogeriatrics 1991; 3:11-22.
135. 134. Prentky R, Burgess AW. Rehabilitation of child molesters: a cost-benefit analysis. Am J Orthopsychiatry 1990;60:108-117.
136. 135. Hyde CE, Harrower-Wilson C, Ash PE. Cost comparison of zuclopenthixol acetate and haloperidol. Psychiatr Bull 1998;22:140-143.
137. 136. Lindholm H, Ljungberg L. Comparison of conventional neuroleptic therapy with depot neuroleptics: an attempt at economic evaluation. Acta Psychiatr Scand 1973;S246: 52-63.
138. 137. Sheehan DM, Atkinson J. Comparative costs of state hospital and community-based inpatient care in Texas: who benefits most. Hosp Commun Psychiatry 1974;25:242-244.
139. 138. Sharfstein SS, Nafzifer JC. Community care: costs and benefits for a chronic patient. Hosp Commun Psychiatry 1976;27:170-173.
140. 139. Kuldau JM, Dirks SJ. Controlled evaluation of a hospital-originated community transitional system. Arch Gen Psychiatry 1977;34:1331-1340.
141. 140. Levenson AJ, Lord CJ, Sermas CE, Thornby JI, Sullender W, Comstock BS. Acute schizophrenia: an efficacious outpatient treatment approach as an alternative to full-time hospitalisation. Dis Nerv System 1997;242-2456.
142. 141. Delaney JA, Seidman E, Willis G. Crisis intervention and the prevention of institutionalization: an interrupted time series analysis. Am J Commun Psychol 1978;6:33-45.
143. 142. Endicott J, Herz MI, Gibbon M. Brief versus standard hospitalisation: the differential costs. Am J Psychiatry 1978;135:708-712.
144. 143. Guillette W, Crowley B, Savitz SA, Goldberg FD. Day hospitalisation as a cost-effective alternative to inpatient care: a pilot study. Hosp Commun Psychiatry 1978;29: 525-527.
145. 144. Jones R, Goldberg D, Hughes B. A comparison of two different services treating schizophrenia: a cost benefit approach. Psychol Med 1980;10:493-505.
146. 145. Levitan SJ, Kornfeld DS. Clinical and cost benefits of liaison psychiatry. Am J Psychiatry 1981;138:790-793.
147. 146. Fenton FR, Tessier L, Contandriopoulos AP, Nguyen H, Struening EL. A comparative trial of home and hospital psychiatric treatment: financial costs. Can J Psychiatry 1982;27:177-187.
148. 147. Gudeman JE, Shore MF, Dickey B. Day hospitalisation and an inn instead of inpatient care for psychiatric patients. N Eng J Med 1983;308:749-753.
149. 148. Hoult J, Renolds I, Charbonneau-Powis M, Weekes P, Briggs J. Psychiatric hospital versus community treatment: the results of a randomised trial. Aust NZ J Psychiatry 1983;17:160-167.
150. 149. Mangen SP, Paykel E, Griffith JH, Buurchell A, Mancini P. Cost-effectiveness of community psychiatric nurse or out-patient psychiatrist care of neurotic patients. Psychol Med 1983;13:407-416.
151. 150. Mueller J, Hopp M. A demonstration of the cost-benefits of case management services for discharged mental patients. Psychiatr Q 1983;55:17-24.
152. 151. Fenton FR, Tessier L, Struening EL et al. A two-year follow-up of a comparative trial of the cost-effectiveness of home and hospital psychiatric treatment. Can J Psychiatry 1984;29:205-211.
153. 152. Mumford E, Schlesinger HJ, Glass GV et al. A new look at cost of reduced cost of medical utilisation following mental health treatment. Am J Psychiatry 1984;141: 1145-1158.
154. 153. Borus JF, Olendzki MC, Kessler L et al. The 'offset effect' of mental health treatment on ambulatory medical care utilisation and charges. Month-by-month and grouped-month analysis of a five-year study. Arch Gen Psychiatry 1985;42:573-580.
155. 154. Dick P, Cameron L, Cohen D, Barlow M, Ince A. Day and full-time psychiatric treatment: a controlled comparison. Br J Psychiatry 1985;14:246-250.
156. 155. Linn MW, Gurel L, Williford WO et al. Nursing home care as an alternative to psychiatric hospitalisation: a veterans administration cooperative study. Arch Gen Psychiatry 1985;42:544-551.
157. 156. Dickey B, Cannon NL, McGuire TG, Gudeman JE. The quarterway house: a two-year cost study of an experimental residential program. Hosp Commun Psychiatry 1986;37:1136-1143.
158. 157. Glick ID, Fleming L, Dechillo N et al. A controlled study of transitional day care for non-chronically-ill patients. Am J Psychiatry 1976;143:1551-1556.
159. 158. Franklin JL, Solovitz B, Mason M, Clemons JR, Miller GE. An evaluation of case management. Am J Pub Health 1987;77:674-678.
160. 159. Holder HD, Blose JO. Changes in health care costs and utilisation associated with mental health treatment. Hosp Commun Psychiatry 1987;38:1070-1075.
161. 160. Holder HD, Blose JO. Mental health treatment and the reduction of health care costs: a four year study of US federal employees' enrolment with the AETNA life insurance company. Adv Health Econ Health Serv Res 1987;8:157-174.
162. 161. Hyde C, Bridges K, Goldberg D, Lowson K, Sterling C, Fargher B. The evaluation of a hostel ward. A controlled study using modified cost-benefit analysis. Br J Psychiatry 1987;151:805-812.
163. 162. Jacobs DF. Cost-effectiveness of specialised psychological programs for reducing hospital stays and out-patient visits. J Clin Psychol 1987;43:729-735.
164. 163. Rappaport M, Goldman H, Thornton P et al. A method for comparing two systems of acute 24-hour psychiatric care. Hosp Commun Psychiatry 1987;38:1091-1095.
165. 164. Wherley M, Bisgaard S. Beyond model programs: evaluation of a countrywide system of residential treatment programs. Hosp Commun Psychiatry 1987;38: 852-857.
166. 165. Bond GR, Miller LD, Krumwied RD, Ward RS. Assertive case management in three CMHCs: a controlled study. Hosp Commun Psychiatry 1988;39:411-418.
167. 166. Gerard K. An appraisal of the cost-effectiveness of alternative day-care settings for frail elderly people. Age Ageing 1988;17:311-318.
168. 167. Santos AB, Thrasher JW, ballenger JC. Decentralised services for public hospital patients: a cost analysis. Hosp Commun Psychiatry 1988;39:827-829.
169. 168. Marinoni A, Grassi M, Ebbli D, Brenna A, Silva S, Torre E. Cost-effectiveness of managing chronic psychotic patients: Italian experience under new psychiatric law. In: Schwefel D et al., ed. Costs and effects of managing chronic psychotic patients. Berlin: Springer, 1988;126-161.
170. 169. Bedell J, Ward JC. An intensive community-based treatment alternative to state hospitalisation. Hosp Commun Psychiatry 1989;40:533-535.
171. 170. Barton WN, Hoy DA, Bonin RL, Gladstone L. Quality of cost-effective management of mental health care. J Occup Med 1989;31:363-367.
172. 171. Creed F, Marks B. Liaison psychiatry in general practice: a comparison of the liaison-attachment scheme and shifted out-patient clinic models. J R Coll Gen Pract 1989; 39:514-517.
173. 172. Dickey B, Binner PR, Leff S, Uyeda MK, Schlesinger MJ, Gudeman JE. Containing mental health treatment costs through program design: a Massachusetts study. Am J Pub Health 1989;79:863-867.
174. 173. Jerrell JM, Hu T. Cost-effectiveness of intensive clinical and case management compared with an existing system of care. Inquiry 1989;26:224-234.
175. 174. Lobeck F, Traxelar WT, Bobinet DD. The cost-effectiveness of a clinical pharmacy service in an outpatient mental health clinic. Hosp Commun Psychiatry 1989; 40:643-645.
176. 175. Coursey RD, Ward-Alexander L, Katz, B. Cost-effectiveness of providing insurance benefits for post-hospital psychiatric halfway houses. Am Psychol 1990;45: 1118-1126.
177. 176. Dickey B, Berren M, Santiago J, Breslau JA. Patterns of service use and costs in model day hospital-inn programs in Boston and Tuscon. Hosp Commun Psychiatry 1990;4:419-424.
178. 177. Glennerster H. The costs of hospital closure: reproviding services for residents of Darenth Park Hospital. Psychiatr Bull 1990;14:140-143.
179. 178. Knapp M, Beecham J, Anderson J et al. The TAPs project. 3. Predicting the community costs of closing psychiatric hospitals. Br J Psychiatry 1990;157:661-670.
180. 179. Thornton PH, Goldman HH, Stegner BL, Rappaport M, Sorensen JE, Attkinsson CC. Assessing the costs and outcomes together. Cost-effectiveness of two systems of acute psychiatric care. Eval Prog Plan 1990;13:231-241.
181. 180. Burns T, Raftery J. Cost of schizophrenia in a randomised trial of home-based treatment. Schizophr Bull 1991;17:407-410.
182. 181. Hu T, Jerrell J. Cost-effectiveness of alternative approaches in treating severely mentally ill in California. Schizophr Bull 1991;17:461-468.
183. 182. Strain JJ, Lyons JS, Hammer JS et al. Cost offset from a psychiatric consultation liaison intervention with elderly hip fracture patients. Am J Psychiatry 1991;148: 1044-1049.
184. 183. Wiersma D, Kluiter H, Niehuis FJ, Ruphan M, Giel R. Costs and benefits of day treatment with community care for schizophrenic patients. Schizophr Bull 1991;17: 411-419.
185. 184. Winegar N, Bistline JL, Sheridan S. Implementing a group therapy program in a managed-care setting: combining cost-effectiveness and quality care. Fam Soc J Contemp Hum Serv 1992;73:56-58.
186. 185. Beecham J, Cambridge P, Hallam A, Knapp M. The costs of domus care. Int J Geriatr Psychiatry 1993;8:827-831.
187. 186. Benglesdorf H, Church JO, Kaye RA, Orlowski B, Alden DC. The cost-effectiveness of crises intervention. Admission diversion savings can offset the high cost of service. J Nerv Ment Dis 1993;181:757-762.
188. 187. Burns T, Raftery J, Beadsmoore A, McGuigan S, Dickson M. A controlled trial of home-based acute psychiatric services. II. Treatment pattern and costs. Br J Psychiatry 1993;163:55-61.
189. 188. Jerrell JM, Hu T, Ridgely MS. Cost-effectiveness of substance disorder interventions for people with severe mental illness. J Ment Health Admin 1994;21:283-297.
190. 189. Knapp M, Cambridge P, Thomason C, Beecham J, Allen C, Darton R. Residential care as an alternative to longstay hospital: a cost-effective evaluation of two pilot projects. Int J Geriatr Psychiatry 1994;9:297-304.
191. 190. McCrone P, Beecham J, Knapp M. Community psychiatric nurse teams: cost-effectiveness of intensive support versus generic care. Br J Psychiatry 1994;165:218-221.
192. 191. Wimo A, Mattsson B, Krakau I, Ericksson T, Nelvig A. Cost-effectiveness analysis of dementia day care of patients with dementia disorders. Health Econ 1994;3: 395-404.
193. 192. Shah AK. Cost comparison of psychogeriatric consultations: out-patient versus home-based consultations. Int Psychogeriatrics 1994;6:179-189.
194. 193. Shah AK. Cost comparison of hospital-based and primary care (general practice health centre) based psychiatric out-patient clinics. Acta Psychiatr Scand 1995;92:30-34.
195. 194. Wiersma D, Kluiter H, Niehuis FJ, Ruphan M, Giel R. Costs and benefits of hospital and day treatment with community care of affective and schizophrenic disorders. Br J Psychiatry 1995;166(Suppl. 27): 52 59.
196. 195. Merson S, Tyrer P, Carlen D, Johnson T. The cost of treatment of psychiatric emergencies: a comparison of hospital and community services. Psychol Med 1996; 26:727-734.
197. 196. Shah AK. Cost of transportation to a psychogeriatric day hospital: minibus versus taxi service. Int J Geriatr Psychiatry 1996;11:555-558.
198. 197. Sledge WH, Tebes J, Wolff N, Helminiak TW. Day hospital/crisis respite care versus inpatient care. Part II. Service utilisation and costs. Am J Psychiatry 1996; 153:1074-1083.
199. 198. Creed F, Mbaya P, Lancashire S, Tomenson B, Williams B, Holme S. Cost-effectivness of day and inpatient psychiatric treatment: results of a randomised controlled trial. Br Med J 1997;314:1381-1385.
200. 199. Gray AM, Marshall M, Lockwood A, Morris J. Problems in conducting economic evaluations alongside clinical trials. Br J Psychiatry 1997;170:47-52.
201. 200. Shah AK. Cost comparison of out-patient and home-based geriatric psychiatry consultation in a service. Ageing Ment Health 1997;1:372-376.
202. 201. Knapp M, Marks I, Wolstenholme J et al. Home-based versus hospital-based care for serious mental illness. Controlled cost-effectiveness study over four years. Br J Psychiatry 1998;172:506-512.
203. 202. Kuipers E, Fowler D, Garety D et al. London East Anglia randomised controlled trial of cognitive-behavioural therapy for psychosis. Br J Psychiatry 1998; 173:61-68.
204. 203. Crnbarioc C, Miljevic CD, Jasovic-Gasic M. Cost benefit of clozapine treatment in type II schizoprenic disorder. Fourth Workshop on Costs and Assessments in Psychiatry, Venice, 1997.
205. 204. Ibrahim SPS. Cost assessment in treatment of substance (heroin) abuse by various methods. Fourth Workshop on Costs and Assessment in Psychiatry, Venice, 1997.
206. 205. Munjiza M, Velickovic M. Cost/benefit analysis of intensive combined family therapy for alcohol dependence. Fourth Workshop on Costs and Assessments in Psychiatry, Venice, 1997.
207. 206. Munjisa M, Velickovic M, Popovic-Deusic S. Cost/benefit analysis of the program for prevention of addictive, multidrug use behaviour with adolescents in Leskovac. Fourth Workshop on Costs and Assessments in Psychiatry, Venice, 1997.